Mode
Text Size
Log in / Sign up
N/A N=162 Randomized Double-blind Treatment

Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery

Thoracic Surgery

Enrolled (actual)
162
Serious AEs
1.2%
Results posted
Jan 2016
Primary outcome: Primary: Determine the Postoperative Complications Found in Each Group — 16; 8; 56; 57 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Atorvastatin (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Memorial Sloan Kettering Cancer Center
Primary completion
May 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Determine the Postoperative Complications Found in Each Group
16; 8; 56; 57

Summary

This study will compare atorvastatin (Lipitor) with a placebo (inactive pill) to see if this drug reduces heart rhythm abnormalities (arrhythmias) or lung inflammation after thoracic surgery. Preliminary results suggest that cholesterol lowering drugs (statins) may reduce problems after surgery such as arrhythmias or lung inflammation which may be serious. This study will be randomized and double blind, meaning that patients are placed in groups purely by chance, like flipping a coin. Neither the patient or doctor will know which group the patient is in.

Eligibility Criteria

Inclusion Criteria

  • Adult patients ≥ 18 yr. scheduled for anatomic lung resection (segmentectomy, lingulectomy, possible or definite lobectomy, bilobectomy, pneumonectomy or extrapleural pneumonectomy) with or without chest wall resection or limited resection
  • Patients with regular cardiac rhythm
  • Patients able to take oral capsules
  • Patients capable of providing written, informed consent
  • Patients without known hepatic or kidney disease

Exclusion Criteria

  • Patients already taking any statin, gemfibrozil (Lopid), or ezetimibe (Zetia)
  • Hypersensitivity to atorvastatin
  • Chronic atrial fibrillation
  • Patients already taking class Ic or III antiarrhythmic drugs
  • Known pregnancy a urine pregnancy test will be given to women of childbearing age
  • Known history of active hepatic disease or known hepatic insufficiency
  • Known history of active kidney disease or insufficiency
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00375518). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search